The research focuses on understanding the role of cxcr4 in colorectal cancer and its potential as both a prognostic marker and a guide for immunotherapy.
Literature review on cxcr4 in colorectal cancer
Analysis of cxcr4 expression levels in tumor samples
Evaluation of therapeutic implications for immunotherapy
Cxcr4 is identified as a significant biomarker associated with poor outcomes in metastatic colorectal cancer.
Higher cxcr4 levels correlate with increased tumor aggressiveness and metastasis.
Potential strategies involving cxcr4 targeting in immunotherapy are discussed.
Abstract
Colorectal cancer (CRC) remains a major global health burden, and despite advances in systemic therapy, outcomes for metastatic disease remain poor.